Harnessing Nanocarriers to Improve Psychiatric Treatment: Progress, Limitations, and Future Directions

利用纳米载体改善精神病治疗:进展、局限性和未来方向

阅读:1

Abstract

To address clinical bottlenecks of traditional antipsychotic drugs, including delayed onset of action, significant peripheral side effects, and poor patient compliance, nanodelivery systems offer a feasible approach through their unique physicochemical properties to improve drug solubility, optimize in vivo transport, and enhance blood-brain barrier (BBB) penetration efficiency. This review focuses on the application potential and translational value of nanodelivery systems in psychiatric disorders. We systematically summarize recent advances in the construction strategies of mainstream nanocarriers, including lipid‑based, polymer‑based, inorganic nanomaterials, Metal-Organic Frameworks (MOFs), and Extracellular Vesicles (EVs), as well as commonly used nanoparticle preparation and characterization techniques. We briefly discuss key challenges facing nanoformulations, such as long‑term safety, large‑scale production, and batch‑to‑batch consistency, and highlight future directions driven by artificial intelligence and precision medicine. This review aims to provide insights for the rational design of nanodelivery systems for psychiatric disorders and to advance the development of precision psychiatry.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。